Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.

Nature Communications
Lindsey R PackTobias Meyer

Abstract

Since their discovery as drivers of proliferation, cyclin-dependent kinases (CDKs) have been considered therapeutic targets. Small molecule inhibitors of CDK4/6 are used and tested in clinical trials to treat multiple cancer types. Despite their clinical importance, little is known about how CDK4/6 inhibitors affect the stability of CDK4/6 complexes, which bind cyclins and inhibitory proteins such as p21. We develop an assay to monitor CDK complex stability inside the nucleus. Unexpectedly, treatment with CDK4/6 inhibitors-palbociclib, ribociclib, or abemaciclib-immediately dissociates p21 selectively from CDK4 but not CDK6 complexes. This effect mediates indirect inhibition of CDK2 activity by p21 but not p27 redistribution. Our work shows that CDK4/6 inhibitors have two roles: non-catalytic inhibition of CDK2 via p21 displacement from CDK4 complexes, and catalytic inhibition of CDK4/6 independent of p21. By broadening the non-catalytic displacement to p27 and CDK6 containing complexes, next-generation CDK4/6 inhibitors may have improved efficacy and overcome resistance mechanisms.

References

Apr 1, 1997·Genes & Development·J LaBaerE Harlow
Nov 19, 2004·Nature·Joan Massagué
Feb 13, 2008·Cell·Asako Sakaue-SawanoAtsushi Miyawaki
Feb 13, 2008·Developmental Cell·Arnaud BessonJames M Roberts
Feb 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Philip J DayHarren Jhoti
Dec 1, 2010·Molecular Biology of the Cell·Thomas D Pollard
Sep 2, 2011·Molecular Biology of the Cell·Grace E PengOrion D Weiner
Apr 30, 2013·Molecular Cell·Miriam Merzel SchachterRobert P Fisher
Jan 6, 2015·Oncotarget·Barbie Taylor-HardingW Ruprecht Wiedemeyer
May 6, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Todd VanArsdaleRobert T Abraham
Aug 15, 2015·Genes & Development·Kate E ColemanJeanette Gowen Cook
Sep 1, 2015·Cell Cycle·Solomon TadesseShudong Wang
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
Apr 1, 2016·Nature Reviews. Clinical Oncology·Ben O'LearyNicholas C Turner
Jan 28, 2017·Nature Reviews. Cancer·Tobias Otto, Piotr Sicinski
May 18, 2017·Cell Reports·Mansi AroraSabrina L Spencer
Sep 12, 2017·PLoS Biology·Sara GookinSabrina L Spencer
Nov 2, 2017·Cell Reports·Stephen T HallettJane A Endicott
Jan 21, 2018·Molecular Cell·Clayton SchwarzJan M Skotheim
Nov 28, 2018·International Journal of Cancer. Journal International Du Cancer·Kamal PandeyYong Wha Moon
Jun 30, 2019·Current Opinion in Cell Biology·Lindsey R PackTobias Meyer
Sep 19, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard S FinnDennis J Slamon
Apr 15, 2020·Cancer Cell·Mónica Álvarez-Fernández, Marcos Malumbres

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

SlideBook
Graphpad Prism
Excel365

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.